Drug intelligence / Profile preview

VagiBIOM

Development stage
Phase 4
Lead developer
Biom Pharmaceutical
Modality
Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration
Vaginal
01

Overview

VagiBIOM is a branded intravaginal probiotic suppository product line designed to restore and maintain a healthy vaginal microbiome and pH, primarily for women with bacterial vaginosis and related urogenital symptoms. It uses a multi-strain Lactobacillus formulation (including Lactobacillus crispatus Bi16, Lactobacillus gasseri Bi19, Bacillus coagulans Bi34, and Lactobacillus acidophilus Bi14) combined with a prebiotic complex, lactic acid, hyaluronic acid, and an oil-based matrix (e.g., coconut oil fatty acids) produced using Biom Pharmaceutical’s LiveBiom fermentation and tissue-adapted biofilm technology, with some commercial variants also incorporating boric acid for additional pH control and antifungal activity.[1][3][5][10] By reseeding beneficial Lactobacillus spp. and acidifying the vaginal environment, VagiBIOM reduces vaginal pH, improves Nugent scores and vaginal health index, and relieves symptoms such as itching and discharge in peri- and premenopausal women with bacterial vaginosis, and is marketed as a natural, microbiome-based adjunct or alternative to conventional antibiotic regimens.[1][3][5][7][10]

Brand names
VagiBIOM
Other names
VagiBIOM vaginal probiotic suppositoryVagiBIOM Lactobacillus suppositoryVagiBIOM vaginal health suppositoriesVagiBIOM boric acid + probiotics suppositories

Beyond the preview

Go deeper on VagiBIOM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VagiBIOM.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call